Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease

Therapeutic Advances in Gastroenterology

Volumn 9, Issue 4, 2016, Pages 463-472

  Briskey, David ^a   Heritage, Mandy ^a   Jaskowski, Lesley Anne ^a   Peake, Jonathan ^b   Gobe, Glenda ^a   Subramaniam, V Nathan ^c,d   Crawford, Darrell ^a   Campbell, Catherine ^a,e   Vitetta, Luis ^f  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c GREENSLOPES PRIVATE HOSPITAL   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^e Envoi Specialist Pathologists   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

dysbiosis; nonalcoholic fatty liver disease; probiotics; steatosis; tight junction proteins

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; PROBIOTIC AGENT; PROTEIN ZO1; PROTEIN ZO2; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIFIDOBACTERIUM; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; LACTOBACILLUS; LIPID DIET; LIPID LIVER LEVEL; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOCOCCUS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84975063068     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X16645055     Document Type: Article

References (32)

1. Alisi A., Bedogni G., Baviera G., Giorgio V., Porro E., Paris C., et al. (2014) Randomised clinical trial: the beneficial effects of Vsl#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 39: 1276-1285.
2. Aller R., De Luis D., Izaola O., Conde R., Gonzalez Sagrado M., Primo D., et al. (2011) Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 15: 1090-1095.
3. Bedogni G., Miglioli L., Masutti F., Tiribelli C., Marchesini G., Bellentani S., (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the DIONYSOS nutrition and liver study. Hepatology 42: 44-52.
4. Bellentani S., Scaglioni F., Marino M., Bedogni G., (2010) Epidemiology of non-alcoholic fatty liver disease. Dig Dis 28: 155-161.
5. Browning J., Szczepaniak L., Dobbins R., Nuremberg P., Horton J., Cohen J., et al. (2004) Prevalence of hepatic steatosis in an urban population in the united states: impact of ethnicity. Hepatology 40: 1387-1395.
6. Hegazy S., El-Bedewy M., (2010) Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol 16: 4145-4151.
7. Hoek J., Pastorino J., (2004) Cellular signaling mechanisms in alcohol-induced liver damage. Semin Liver Dis 24: 257-272.
8. Jiang W., Wu N., Wang X., Chi Y., Zhang Y., Qiu X., et al. (2015) Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep 5: 8096.
9. Khimji A., Shao R., Rockey D., (2008) Divergent transforming growth factor-beta signaling in hepatic stellate cells after liver injury: functional effects on ECE-1 regulation. The American journal of pathology 173: 716-727.
10. Kleiner D., Brunt E., Van Natta M., Behling C., Contos M., Cummings O., et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321.
11. Marchesini G., Moscatiello S., Di Domizio S., Forlani G., (2008) Obesity-associated liver disease. J Clin Endocrinol Metab 93: S74-80.
12. Mouzaki M., Comelli E., Arendt B., Bonengel J., Fung S., Fischer S., et al. (2013) Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 58: 120-127.
13. Mykhal'chyshyn H., Bodnar P., Kobyliak N., (2013) Effect of probiotics on proinflammatory cytokines level in patients with type 2 diabetes and nonalcoholic fatty liver disease. Lik Sprava 2: 56-62.
14. Nabavi S., Rafraf M., Somi M., Homayouni-Rad A., Asghari-Jafarabadi M., (2014) Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci 97: 7386-7393.
15. Niaz A., Ali Z., Nayyar S., Fatima N., (2011) Prevalence of NAFLD in healthy and young male individuals. ISRN Gastroenterol 2011: 363546.
16. Nussbaum J., Liu L., Hasan S., Schaub M., McClendon A., Stainier D., et al. (2013) Homeostatic generation of reactive oxygen species protects the zebrafish liver from steatosis. Hepatology 58: 1326-1338.
17. Otte J., Mahjurian-Namari R., Brand S., Werner I., Schmidt W., Schmitz F., (2009) Probiotics regulate the expression of Cox-2 in intestinal epithelial cells. Nutr Cancer 61: 103-113.
18. Parassol N., Freitas M., Thoreux K., Dalmasso G., Bourdet-Sicard R., Rampal P., (2005) Lactobacillus casei DN-114 001 inhibits the increase in paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells. Res Microbiol 156: 256-262.
19. Peterson L., Artis D., (2014) Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol 14: 141-153.
20. Resta-Lenert S., Barrett K., (2003) Live Probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (Eiec). Gut 52: 988-997.
21. Rodes L., Khan A., Paul A., Coussa-Charley M., Marinescu D., Tomaro-Duchesneau C., et al. (2013) Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol 23: 518-526.
22. Sepideh A., Karim P., Hossein A., Leila R., Hamdollah M., Mohammad E., et al. (2015) Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial. J Am Coll Nutr: 1-6.
23. Shing C., Peake J., Lim C., Briskey D., Walsh N., Fortes M., et al. (2014) Effects of probiotics supplementation on gastrointestinal permeability, inflammation and exercise performance in the heat. Eur J Appl Physiol 114: 93-103.
24. Spadoni I., Zagato E., Bertocchi A., Paolinelli R., Hot E., Di Sabatino A., et al. (2015) A Gut-vascular barrier controls the systemic dissemination of bacteria. Science 350: 830-834.
25. Tan T., Crawford D., Jaskowski L., Murphy T., Heritage M., Subramaniam V., et al. (2011) Altered lipid metabolism in HFE-knockout mice promotes severe NAFLD and early fibrosis. Am J Physiol Gastrointest Liver Physiol 301: G865-876.
26. Tapiainen T., Ylitalo S., Eerola E., Uhari M., (2006) Dynamics of gut colonization and source of intestinal flora in healthy newborn infants. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica 114: 812-817.
27. Tilg H., Diehl A., (2000) Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 343: 1467-1476.
28. Vitetta L., Manuel R., Zhou J., Linnane A., Hall S., Coulson S., (2014) The overarching influence of the gut microbiome on end-organ function: the role of live probiotic cultures. Pharmaceuticals (Basel) 7: 954-989.
29. Waller-Evans H., Hue C., Fearnside J., Rothwell A., Lockstone H., Calderari S., et al. (2013) Nutrigenomics of high fat diet induced obesity in mice suggests relationships between susceptibility to fatty liver disease and the proteasome. PLoS One 8: e82825.
30. Wong V., Won G., Chim A., Chu W., Yeung D., Li K., et al. (2013) Treatment of nonalcoholic steatohepatitis with probiotics. a proof-of-concept study. Ann Hepatol 12: 256-262.
31. Zhu L., Baker S., Gill C., Liu W., Alkhouri R., Baker R., et al. (2013) Characterization of gut microbiomes in nonalcoholic steatohepatitis (nash) patients: a connection between endogenous alcohol and nash. Hepatology 57: 601-609.
32. Zyrek A., Cichon C., Helms S., Enders C., Sonnenborn U., Schmidt M., (2007) Molecular mechanisms underlying the probiotic effects of Escherichia coli nissle 1917 involve ZO-2 and pkczeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 9: 804-816.